# NCT04176198 (NCT04176198)

> A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04176198
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Sumitomo Pharma America, Inc.
- Conditions: Myelofibrosis
- Interventions: Nusivertib; Ruxolitinib; Momelotinib
- Enrollment: 240
- Primary outcome: Determine the incidence of dose-limiting toxicities (DLTs)
- Primary outcome: Determine the incidence of treatment emergent adverse events
- Primary outcome: Assess patients for any evidence of preliminary activity by determining the number of patients with ≥ 35% spleen volume reduction (SVR35)

## Indexed commentary on NCT04176198 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04176198